Ernexa Therapeutics Inc.
ERNA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000748592
No open-market purchases or sales by Ernexa Therapeutics Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $236.2K in total; no superinvestor holds it.
Other share classesERNAW
13F holders, Q1 2026
Institutional positions in Ernexa Therapeutics Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +7 vs. Q4 2025
- Shares held
- 3.57M
- +3.09M (+634.3%) vs. Q4 2025
- Total value
- $711.4K
- +$127.4K (+21.8%) vs. Q4 2025
- New holders
- 11
- 3 more added
- Sold out
- 4
- 0 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ERNA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 10 | $236.2K |
| Q1 2026 | 20 | $711.4K |
| Q4 2025 | 14 | $627.1K |
| Q3 2025 | 14 | $566.0K |
| Q2 2025 | 12 | $91.7K |
| Q1 2025 | 27 | $264.2K |
| Q4 2024 | 24 | $292.4K |
| Q3 2024 | 20 | $746.9K |
| Q2 2024 | 20 | $712.4K |
| Q1 2024 | 23 | $981.1K |
| Q4 2023 | 20 | $636.9K |
| Q3 2023 | 22 | $728.4K |
| Q2 2023 | 20 | $750.2K |
| Q1 2023 | 21 | $1.14M |
| Q4 2022 | 20 | $1.19M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Ernexa Therapeutics Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bleichroeder LP | 2,000,000 | $398.0K | 0.07% | +2,000,000 | New |
| Dauntless Investment Group, LLC | 612,443 | $121.9K | 0.34% | +612,443 | New |
| CI Private Wealth, LLC | 438,093 | $87.2K | 0.00% | +10.0% | Added |
| Geode Capital Management, LLC | 244,446 | $48.6K | 0.00% | +220,829+935.0% | Added |
| XTX Topco Ltd | 54,338 | $10.8K | 0.00% | +54,338 | New |
| Warberg Asset Management LLC | 50,000 | $10.1K | 0.00% | +50,000 | New |
| Jane Street Group, LLC | 41,167 | $8.19K | 0.00% | +41,167 | New |
| Citadel Advisors LLC | 33,076 | $6.58K | 0.00% | +33,076 | New |
| Vanguard Capital Management LLC | 26,504 | $5.27K | 0.00% | +26,504 | New |
| Vanguard Fiduciary Trust Co | 25,447 | $5.06K | 0.00% | +25,447 | New |
| UBS Group AG | 21,233 | $4.22K | 0.00% | +20,633+3,438.8% | Added |
| Goldman Sachs Group Inc | 16,631 | $3.31K | 0.00% | +16,631 | New |
| Sippican Capital Advisors | 10,000 | $1.99K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 820 | $163 | 0.00% | 00.0% | Unchanged |
| Assetmark, Inc | 133 | $26 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 10 | $2 | 0.00% | 00.0% | Unchanged |
| Montag A & Associates Inc | 8 | $2 | 0.00% | 00.0% | Unchanged |
| Activest Wealth Management | 3 | $1 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 6 | $1 | 0.00% | +6 | New |
| Caitong International Asset Management Co., Ltd | 1 | $0 | 0.00% | +1 | New |
| HRT Financial LP | 0 | $0 | 0.00% | −12,625−100.0% | Sold out |
| Fortitude Family Office, LLC | 0 | $0 | 0.00% | −804−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −34−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |